Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2CNS 1

Conditions

Sarcoma, Ewing 2Osteosarcoma 2Rhabdoid Tumor 1Neuroectodermal Tumors, Primitive 1Neuroblastoma 1Diffuse Intrinsic Pontine Glioma 1

Interventions

Cyclophosphamide 4Vincristine 3Temozolomide 3Magnetic Resonance Spectroscopy 3Ifosfamide 3Etoposide 3Doxorubicin 3ulixertinib 2tipifarnib 2selpercatinib 2liposomal doxorubicin 2ivosidenib 2cabozantinib 2X-Rays 2Topotecan 2Specimen Handling 2Radiation 2Phantoms, Imaging 2Nuclear Medicine Department, Hospital 2Irinotecan 2Eflornithine 2Congresses as Topic 2trifluridine tipiracil drug combination 1tazemetostat 1talazoparib 1palbociclib 1olaparib 1larotrectinib 1irinotecan sucrosofate 1ganitumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Sarcoma, Ewing × Eflornithine × 30 days × Clear all
NCT06465199 2026-06-03

Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas

Milton S. Hershey Medical Center

Phase 1/2 Recruiting
289 enrolled
CNSSarcoma

Diffuse Intrinsic Pontine Glioma, Neuroblastoma, Sarcoma, Ewing, Osteosarcoma, Neuroectodermal Tumors, Primitive, Rhabdoid Tumor

NCT07321912 2026-05-26

Eflornithine (DFMO) for Ewing Sarcoma and Osteosarcoma

Milton S. Hershey Medical Center

Phase 2 Recruiting
406 enrolled
Sarcoma

Sarcoma, Ewing, Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡